Benninger Lauryn A, Trillo Cesar, Lascano Jorge
Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida College of Medicine, Gainesville, Florida.
Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida College of Medicine, Gainesville, Florida.
J Heart Lung Transplant. 2021 Dec;40(12):1498-1501. doi: 10.1016/j.healun.2021.08.009. Epub 2021 Aug 26.
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapy has previously been contraindicated in solid organ transplant recipients. This was due to lack of data and concern for interactions with immunosuppressive drug regimens. However, in post-lung transplant recipients, CFTR modulators may improve extrapulmonary manifestations of cystic fibrosis without impacting graft function or immunosuppressive drug levels. Herein, we present our single center experience with the use of elexacaftor/tezacaftor/ivacaftor, Trikafta, in adult post-lung transplant recipients.
囊性纤维化跨膜传导调节因子（CFTR）调节剂疗法此前在实体器官移植受者中被列为禁忌。这是由于缺乏数据以及担心与免疫抑制药物方案相互作用。然而，在肺移植术后受者中，CFTR调节剂可能会改善囊性纤维化的肺外表现，而不会影响移植器官功能或免疫抑制药物水平。在此，我们介绍我们单中心使用依列卡福/替扎卡福/依伐卡福（三联疗法）治疗成年肺移植术后受者的经验。
